Daniela Weiskopf1, Michael A Angelo1, Alba Grifoni1, Patrick H O'Rourke1, John Sidney1, Sinu Paul1, Aruna D De Silva2, Elizabeth Phillips3, Simon Mallal3, Sunil Premawansa4, Gayani Premawansa5, Ananda Wijewickrama6, Bjoern Peters1, Alessandro Sette1. 1. Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, California. 2. Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, California Genetech Research Institute. 3. Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia. 4. Department of Zoology and Environmental Science, Science Faculty, University of Colombo. 5. North Colombo Teaching Hospital, Ragama. 6. National Institute of Infectious Diseases, Gothatuwa, Sri Lanka.
Abstract
BACKGROUND: Each year dengue virus (DENV) infects 400 million human but causes symptomatic disease in only a subset of patients, suggesting that host genetic factors may play a role. HLA molecules that restrict T-cell responses are one of the most polymorphic host factors in humans. METHODS: Here we map HLA DRB1-restricted DENV-specific epitopes in individuals previously exposed to DENV, to identify the breadth and specificity of CD4(+) T-cell responses. To investigate whether HLA-specific variations in the magnitude of response might predict associations between dengue outcomes and HLA-DRB1 alleles, we assembled samples from hospitalized patients with known severity of disease. RESULTS: The capsid protein followed by nonstructural protein 3 (NS3), NS2A, and NS5 were the most targeted proteins. We further noticed a wide variation in magnitude of T-cell responses as a function of the restricting DRB1 allele and found several HLA alleles that showed trends toward a lower risk of hospitalized disease were associated with a higher magnitude of T-cell responses. CONCLUSIONS: Comprehensive identification of unique CD4(+) T-cell epitopes across the 4 DENV serotypes allows the testing of T-cell responses by use of a simple, approachable technique and points to important implications for vaccine design.
BACKGROUND: Each year dengue virus (DENV) infects 400 million human but causes symptomatic disease in only a subset of patients, suggesting that host genetic factors may play a role. HLA molecules that restrict T-cell responses are one of the most polymorphic host factors in humans. METHODS: Here we map HLA DRB1-restricted DENV-specific epitopes in individuals previously exposed to DENV, to identify the breadth and specificity of CD4(+) T-cell responses. To investigate whether HLA-specific variations in the magnitude of response might predict associations between dengue outcomes and HLA-DRB1 alleles, we assembled samples from hospitalized patients with known severity of disease. RESULTS: The capsid protein followed by nonstructural protein 3 (NS3), NS2A, and NS5 were the most targeted proteins. We further noticed a wide variation in magnitude of T-cell responses as a function of the restricting DRB1 allele and found several HLA alleles that showed trends toward a lower risk of hospitalized disease were associated with a higher magnitude of T-cell responses. CONCLUSIONS: Comprehensive identification of unique CD4(+) T-cell epitopes across the 4 DENV serotypes allows the testing of T-cell responses by use of a simple, approachable technique and points to important implications for vaccine design.
Authors: Daniela Weiskopf; Michael A Angelo; Elzinandes L de Azeredo; John Sidney; Jason A Greenbaum; Anira N Fernando; Anne Broadwater; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Kimberly A Mattia; Benjamin J Doranz; Howard M Grey; Sujan Shresta; Bjoern Peters; Alessandro Sette Journal: Proc Natl Acad Sci U S A Date: 2013-04-11 Impact factor: 11.205
Authors: Tobias Zellweger; Kim Chi; Hideaki Miyake; Hans Adomat; Satoshi Kiyama; Kirsten Skov; Martin E Gleave Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: Maya F Kotturi; Bjoern Peters; Fernando Buendia-Laysa; John Sidney; Carla Oseroff; Jason Botten; Howard Grey; Michael J Buchmeier; Alessandro Sette Journal: J Virol Date: 2007-02-28 Impact factor: 5.103
Authors: Maya F Kotturi; Iain Scott; Tom Wolfe; Bjoern Peters; John Sidney; Hilde Cheroutre; Matthias G von Herrath; Michael J Buchmeier; Howard Grey; Alessandro Sette Journal: J Immunol Date: 2008-08-01 Impact factor: 5.422
Authors: Nalaka Kanakaratne; Wahala M P B Wahala; William B Messer; Hasitha A Tissera; Aruna Shahani; Nihal Abeysinghe; Aravinda M de-Silva; Maya Gunasekera Journal: Emerg Infect Dis Date: 2009-02 Impact factor: 6.883
Authors: Randi Vita; James A Overton; Jason A Greenbaum; Julia Ponomarenko; Jason D Clark; Jason R Cantrell; Daniel K Wheeler; Joseph L Gabbard; Deborah Hix; Alessandro Sette; Bjoern Peters Journal: Nucleic Acids Res Date: 2014-10-09 Impact factor: 16.971
Authors: Alba Grifoni; Michael Angelo; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Jason Botten; Jonathan Boyson; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf Journal: J Virol Date: 2017-03-29 Impact factor: 5.103
Authors: Michael A Angelo; Alba Grifoni; Patrick H O'Rourke; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf Journal: J Virol Date: 2017-02-14 Impact factor: 5.103
Authors: Zoe Moodie; Michal Juraska; Ying Huang; Yingying Zhuang; Youyi Fong; Lindsay N Carpp; Steven G Self; Laurent Chambonneau; Robert Small; Nicholas Jackson; Fernando Noriega; Peter B Gilbert Journal: J Infect Dis Date: 2018-02-14 Impact factor: 5.226
Authors: Veena S Patil; Ariel Madrigal; Benjamin J Schmiedel; James Clarke; Patrick O'Rourke; Aruna D de Silva; Eva Harris; Bjoern Peters; Gregory Seumois; Daniela Weiskopf; Alessandro Sette; Pandurangan Vijayanand Journal: Sci Immunol Date: 2018-01-19